Document:

CONSULTING SERVICES AGREEMENT

This  AGREEMENT  ("AGREEMENT")  is entered into as of June 7, 2005,  by DNAPrint
genomics, Inc. 900 Cocoanut Ave. Sarasota, FL 34236, USA ("DNAP") and DR. ARTHUR
J. SYTKOWSKI residing at 203 Park Avenue,  Arlington,  Massachusetts  02476, USA
("DR. SYTKOWSKI").

                                   WITNESSETH:

      WHEREAS,  DNAP is engaged in a project (the  "PROJECT")  relating to human
erythropoietin (the "FIELD"); and

      WHEREAS,  DR.  SYTKOWSKI has knowledge and expertise  regarding the FIELD;
and

      WHEREAS,  DNAP  desires  to  make  use of the  specialized  knowledge  and
expertise of DR. SYTKOWSKI as a consultant in the FIELD; and

      WHEREAS,  DR. SYTKOWSKI has advised DNAP of his  willingness,  ability and
desire to provide  consulting and advisory services to it in connection with the
FIELD;

NOW,  THEREFORE,  in  consideration  of  the  mutual  covenants  and  conditions
contained herein, DR. SYTKOWSKI, and DNAP agree as follows:

1.  ENGAGEMENT - DNAP hereby  engages DR.  SYTKOWSKI  and DR.  SYTKOWSKI  hereby
agrees to hold himself available and to render,  at DNAP's request,  independent
advisory and consulting  services,  in compliance  with the terms and conditions
set forth herein and all applicable laws, statutes and regulations.

2.  SERVICES  AND DUTIES - DR.  SYTKOWSKI  agrees  that  during the term of this
AGREEMENT and any subsequent  extension(s) thereof, he will provide his services
as a consultant to DNAP in the FIELD.  DR.  SYTKOWSKI's  responsibilities  shall
include, but shall not be limited to, the following services:

                                       1
<PAGE>

a. Consulting on all matters involving the FIELD, including, without limitation,
implementation of analytics,  purification,  medical uses, regulatory issues and
patent affairs;

b. Advising and training personnel designated by DNAP in the FIELD technology;

c. Advising on the status of FIELD- related patents and prosecutions;

d. Advising on clinical trials, medical uses and side effects of the FIELD;

e. Providing information on new developments in the FIELD;

f. Providing expertise and introduction to Dr. Sytkowski's  personal contacts in
the  FIELD,  including  without  limitation,   scientific,   medical,   biotech,
regulatory and patent issues; and,

g. Completing the Milestone Tasks described on the attached Exhibit "A".

DR. SYTKOWSKI further agrees to render his services conscientiously,  consistent
with the highest standards of his profession, and to devote, subject to existing
professional  duties,  the  requisite  time,  effort and  abilities  required to
satisfactorily perform his obligations during the term of this AGREEMENT and any
subsequent  extension(s) thereto, and to do so in such reasonable manner as DNAP
and DR. SYTKOWSKI shall mutually agree.

3. PAYMENT - As full  consideration for the services  performed by DR. SYTKOWSKI
hereunder, DNAP agrees to compensate DR. SYTKOWSKI as follows:

      a.  SIXTY  THOUSAND  ($  60,000.00)  U.S.  DOLLARS to be paid in six equal
monthly  installments of TEN THOUSAND  ($10,000.00) U.S.  DOLLARS.  Each payment
will be made within  THIRTY  (30) DAYS of the first day of each month,  with the
first month commencing on the date of execution hereof.

      b. Upon  presentation of receipts,  DNAP will reimburse DR.  SYTKOWSKI for
reasonable out-of-pocket expenses incurred in connection with services performed
under this  AGREEMENT,  including  but not limited to airfare,  lodging,  meals,
taxis, trains,  extraordinary  fee-based computer searches and the like. Flights
of greater  than two (2) hours will be business  class or the next higher  class
above economy, if DR. SYTKOWSKI so chooses.  DR. SYTKOWSKI will invoice DNAP for
such travel and other expenses  promptly  after  incurring such charges and DNAP
agrees to pay such invoices, subject to the conditions of this paragraph, within
THIRTY (30) DAYS of their receipt.

      c. DNAP agrees to reimburse  DR.  SYTKOWSKI for airfare,  lodging,  meals,
taxis,  trains,  and all other  reasonable  out-of-pocket  expenses  incurred in
conjunction   with   attending   two   scientific/medical,    biotechnology   or
pharmaceutical  related  meetings per year,  said meetings to relate directly to
the FIELD and/or to DR. SYTKOWSKI's  consulting and advisory services under this
AGREEMENT.  DR.  SYTKOWSKI  shall obtain DNAP's  consent prior to incurring such
expenses.  DR.  SYTKOWSKI  agrees to invoice DNAP promptly after  incurring such
charges and DNAP agrees to pay such  invoices  within  THIRTY (30) DAYS of their
receipt.

                                       2
<PAGE>

      d. In recognition of DR.  SYTKOWSKI's  knowledge and skill, DNAP agrees to
make five  separate  incentive  payments to DR.  SYTKOWSKI at the rate of TWENTY
FIVE THOUSAND  ($25,000.00)  U.S.  DOLLARS per year to be paid on or before each
anniversary of the date of execution hereof.

4. MILESTONE  CONTINGENT  PAYMENTS- DNAP agrees to make the following  milestone
payments to DR. SYTKOWSKI following the completion of the described event to the
satisfaction  of DNAP,  and to the extent DR.  SYTKOWSKI  has not  received  any
monies from Beth Israel Deaconess  Medical Center ("BIDMC") under any agreements
between DR. SYTKOWSKI and BIDMC relating to the described event:

      a.    Initiation  of the  first  Phase I  trial  of an  erythropoietin  or
            erythropoietin-related  product,  TWENTY FIVE THOUSAND  ($25,000.00)
            U.S. DOLLARS.
      b.    Initiation  of the  first  Phase II trial  of an  erythropoietin  or
            erythropoietin-related  product,  TWENTY FIVE THOUSAND  ($25,000.00)
            U.S. DOLLARS.
      c.    First    regulatory     approval    of    an    erythropoietin    or
            erythropoietin-related  product,  TWENTY FIVE THOUSAND  ($25,000.00)
            U.S. DOLLARS.
      d.    First commercial sale of an erythropoietin or erythropoietin-related
            product, FIFTY THOUSAND ($50,000.00) U.S. DOLLARS.

DNAP's  obligation to make these  payments to DR.  SYTKOWSKI will extend for ten
(10) years beyond the term of this  AGREEMENT,  or any  termination,  renewal or
extension  thereof.  Any payments DR. SYTKOWSKI  receives from BIDMC relating to
the  described  events  shall  reduce,  dollar for  dollar,  DNAP's  obligations
hereunder.

5.  INDEMNIFICATION  - DNAP  shall  indemnify,  defend  and  hold  harmless  DR.
SYTKOWSKI and his employees and agents and their  respective  heirs,  successors
and assigns (the "INDEMNITEES"), against any liability, damage, loss, or expense
(including  attorneys' fees and expenses of litigation)  actually incurred by or
imposed upon the  INDEMNITEES or any one of them in connection  with any claims,
suits,  actions,  demands, or judgments of any party other than DNAP arising out
of or  relating  to the  PROJECT,  including,  but not limited to, any theory of
product liability  (including but not limited to, strict  liability)  concerning
any  products,  process or service  made,  used or sold  pursuant  to any rights
granted  under this  AGREEMENT.  DNAP's  indemnification  shall not apply to any
claim, suit,  action,  demand,  loss or expense  (including  attorneys' fees and
expenses of litigation) to the extent that it is actually incurred or imposed or
is due to the breach of this  AGREEMENT,  violation of or failure to comply with
any  law,  or  governmental  regulation,   negligence,  reckless  MISCONDUCT  or
intentional MISCONDUCT  (hereinafter  collectively the " MISCONDUCT ") of any of
the INDEMNITEES.

6.  CONFIDENTIALITY  - In view of the  proprietary  rights and interests of DNAP
concerning the PROJECT and their facilities and technology, DR. SYTKOWSKI agrees
that during the term of this AGREEMENT and any subsequent  extension(s) thereto,
and for a period of three (3) years  thereafter,  DR.  SYTKOWSKI  shall  hold in
strictest  confidence  and not use for his own benefit or for the benefit of any
third party any information  concerning the PROJECT and DNAP  (including  DNAP's
security and computer  systems) or the FIELD which is disclosed to DR. SYTKOWSKI

                                       3
<PAGE>

by DNAP or that results from his services under this AGREEMENT. Such information
includes,  but is not  limited  to,  confidential  or  proprietary  information,
discoveries,  results,  methodology,  codes, passwords,  materials,  technology,
know-how,  financial  and other data,  both  technical  and  non-technical.  DR.
SYTKOWSKI  shall  not  disclose  nor  cause  nor  permit  to be  disclosed  such
information to any third party or use such  information for any purpose,  except
as provided  herein,  without the prior written  approval of DNAP. The foregoing
restrictions  and obligations of DR. SYTKOWSKI shall not apply to any portion of
such information which:

a. Is or later becomes generally available to the public by use,  publication or
the like, through no fault of DR. SYTKOWSKI;

b. Is obtained  from a third party who had the legal right to disclose  the same
to DR. SYTKOWSKI; or

c. Is already possessed by DR.  SYTKOWSKI,  as evidenced by his written records,
predating receipt thereof from DNAP.

Specific  information  disclosed to DR. SYTKOWSKI by DNAP shall not be deemed to
be  available  to the  public or in prior  possession  of DR.  SYTKOWSKI  merely
because  such  specific  information  is  embraced by more  general  information
available to the public or in the prior possession of DR. SYTKOWSKI.

7.  RIGHT TO  DISCLOSE  - DR.  SYTKOWSKI  agrees  that  during  the term of this
AGREEMENT,  he will not  disclose  to DNAP any  information  which he is under a
contractual or other legal obligation to a third party not to disclose.

8. TERM,  TERMINATION  AND EXTENSION OF THIS AGREEMENT - This AGREEMENT shall be
effective for a six (6) month Period  beginning June 1, 2005 and ending November
30, 2005.

Either party may terminate  this  AGREEMENT upon thirty (30) days written notice
to the other party. If DNAP terminates this AGREEMENT for DR. SYTKOWSKI's breach
of this AGREEMENT, or Dr. Sytkowski's violation of or failure to comply with any
law, or governmental regulation,  negligence or MISCONDUCT,  DR. SYTKOWSKI shall
not be entitled  to receive  the  Milestone  payments  referenced  in Section 4,
above.  Any rights or obligations  set forth herein,  which are accrued prior to
the termination of this AGREEMENT,  shall survive termination of this AGREEMENT.
Negotiations  may  be  initiated  at  the  request  of  either  party  prior  to
termination  of this Agreement to extend this  Agreement.  If the parties do not
agree on an extension in writing prior  toNovember 15, 2005, the AGREEMENT shall
terminate on November 30, 2005.

9. INDEPENDENT CONTRACTOR For the purpose of this AGREEMENT, DR. SYTKOWSKI shall
be an  independent  contractor  of DNAP without the  authority to bind or act as
agent for DNAP or its employees for any purpose,  and nothing in this  AGREEMENT
shall be construed to create any joint venture or  partnership  among or between
the parties.

                                       4
<PAGE>

10. PUBLICITY. Neither party will use the name of the other party in publication
or advertising  involving this AGREEMENT without the other party's prior written
approval.

11.  WARRANTIES  The parties  warrant and represent  that they have the right to
enter into and perform  this  AGREEMENT.  DR.  SYTKOWSKI  further  warrants  and
represents that he knows of no conflict  between the terms of this AGREEMENT and
any other contractual or other obligations,  expressed or implied,  which he may
have with anyone,  including but not limited to his  contractual  obligations to
Beth Israel Deaconess Medical Center.

12.  GOVERNING  LAW  This  AGREEMENT  shall  be  governed  by  the  laws  of the
Commonwealth of Massachusetts,  USA, and DR. SYTKOWSKI and DNAP hereby submit to
the exclusive jurisdiction of the Massachusetts Courts, both State and Federal.

13. AMENDMENTS. No modification to this AGREEMENT shall be effective unless made
in writing and signed by a duly authorized representative of each party.

14. NOTICES. All notices required or permitted to be given hereunder shall be in
writing and given to each of the other parties  hereto by delivery to its or his
respective address as first set forth above (i) personal delivery,  (ii) courier
service or registered  or certified  air mail (postage  prepaid) or (iii) by fax
(with a copy by  registered  or certified  air mail).  All such notices shall be
effective when received by the addressee.

15. TAXES. Each party shall be responsible for his or its own tax obligations as
imposed by any governmental authority having jurisdiction.

16. ASSIGNMENT.  This Agreement may not be assigned without the parties' express
written  consent.  Any purported  assignment of this Agreement is void and of no
effect.

IN WITNESS  WHEREOF,  the parties have executed  this  AGREEMENT as of dates set
forth below:

DR. ARTHUR J. SYTKOWSKI                  DNAPrint genomics, Inc.

Date: June 7, 2005                       Name (print):

Place:                                   Date: June 7, 2005

Signature: /s/ Arthur J. Sytkowski       Place:

                                         Signature: /s/ Richard Gabriel

                                       5
<PAGE>

                              ARTHUR SYTKOWSKI, MD

                      MILESTONES (TASKS) FOR FIRST 6 MONTHS

                                  June 7, 2005

1.    Supervise  sequencing  of the Epo-Epo  fusion  protein  gene that has been
      transfected into CHO cells (3 weeks).

      o     If the gene sequence contains portions that are not acceptable,  the
            gene  will  have to be  reconstructed  and a new cell  line  will be
            prepared (3 months).

2.    Transfer living CHO cell cultures to Contract Research Organization (CRO).

3.    Interact with CRO personnel including transfer of and training in analytic
      techniques.(6 months).

4.    Supervise in vitro bioassays of samples provided by CRO (6 months).

5.    Supervise the  determination  of biologic  activities of longer Epo fusion
      proteins.  This will be carried out  depending  upon the need to prepare a
      new cell line (see # 1).

                                       6Exhibit
      10.1

	 	 	 
	 	 	
      
      Digital
      Learning Management Corporation

      19950
      Mariner Avenue.

      Torrance,
      Calif. 90503 (USA)

      Phone:
      (310) 921-3444; Fax: (310) 921-2878

      www.dlmcweb.com

       

       

 

AGREEMENT
TO SETTLE OUTSTANDING DISPUTES BETWEEN DLMC/GLOBAL AND MACK
MAHMOOD

This
Agreement is made between Mack Mahmood and (hereafter referred to as “Mack”),
and Digital Learning Management Corporation and Global Computer Systems, Inc.,
(hereafter referred to as “DLMC or GLOBAL or Company” as the context
requires).In consideration of the promises hereafter set forth, both Mack and
DLMC agree as follows: 

	1.  	
      VAR
      AGREEMENT.
      The Company agrees that it will offer a non-exclusive Value Added Reseller
      (“VAR”) opportunity to Mack Mahmood as an individual or to a Business
      Entity registered by Mack Mahmood. This standard DLMC VAR agreement is to
      include a provision allowing Mack Mahmood or his new company the right to
      purchase 10 (ten) Units (any model ) of the Company’s Virtual University
      Appliance System at a 60% discount off the published list price . For all
      such Purchases Company will extend up to 90 days payment terms to Mack
      Mahmood or the company owned by Mack Mahmood upon approval of the credit
      of his End-customers and its payment to MAC Mahmood as a security. The
      price allowance will be valid for 12 months from signing this agreement.
      The agreement will be automatically renewed fro another 12 months in the
      event Mack or his designate company is not able to sell ten units in the
      first 12 months. If for any of the first 10 units, a sale is facilitated
      by Mack Mahmood directly for the Company, the Company will pay Mack
      Mahmood 60% commissions on that sale. 

	2.  	
      SALE
      OF FURNITURE, EQUIPMENT AND INVENTORY.
      The Company agrees to sell for $1 (One dollar) all furniture, fixtures,
      inventory and equipment (collectively hereafter referred to as ‘items”)
      that the Company removed from Global’s Irvine facility and items not
      removed from the said facility which are in possession of Mack Mahmood
      personally. DLMC/Global will issue a Bill-of-Sale of these items to Mack.
      Mack will be permitted to store these items at no charge at DLMC’s Mariner
      Building Warehouse located at 19950 Mariner Ave., Torrance, California as
      long as the current owners of the Mariner Building have ownership control
      of that facility. 

	3.  	
      IDEMNIFICATION
      ON UNION BANK LOAN/CREDIT LINE.
      Mack agrees that he will Indemnify and hold harmless DLMC for any guaranty
      and undertaking which was provided by DLMC to Mack and Aslam Ali for the
      Union Bank Credit Line Loan under the transaction in which DLMC purchased
      all Global stock from Aslam Ali and Mack, pursuant to an agreement dated
      April 30, 2004..

Digital
Learning Management Corporation - Non-Stop Education

Page
1 of 
3 

	 	 	
      
       

	 	 	 
	 	 	
      
      Digital
      Learning Management Corporation

      19950
      Mariner Avenue.

      Torrance,
      Calif. 90503 (USA)

      Phone:
      (310) 921-3444; Fax: (310) 921-2878

      www.dlmcweb.com

       

	4.  	
      PROSOFT
      ACCOUNT & OTHER SALES LEADS.
      Upon signing of the VAR agreement, the Company will offer Mack an Account
      Management option to manage the Company’s VU Appliance Sales relationship
      with ProSoft. Mack Mahmood has the choice to take up this option if he so
      desires and is available to do so. The terms of said option will be in
      accordance with the terms of the VAR agreement to be signed under
      paragraph 1 of this agreement. The Company will offer a 20% commission to
      Mack for the sales, sales support, training and other services provided by
      the Company to ProSoft and ProSoft customers. Mack agrees to make
      reasonable and demonstrable efforts and make himself available to support
      the Company’s efforts to close the transactions either directly or with
      the Company’s assistance and complies with the terms of the VAR Agreement.
      All commissions will be paid to Mack by the Company no later than 15
      working days after collection of the funds from such
  Sales.

	5.  	
      SALES
      LEADS: In
      an effort to assist Mack with his VAR efforts, the Company agrees to pass
      on to Mack certain ‘hot leads’ where product has not yet been sold to the
      customer by the Company. The Company acknowledges that Mack may have
      generated some such leads prior to his disengagement with the Company. The
      Company will make reasonable efforts to provide him with those leads
      first.

	6.  	
      PAYMENT
      OF PAST DUE RENT.
      The Company agrees to execute a settlement Agreement for payment of two
      months of past due rent for the Irvine facility (Global’s rented facility)
      to the Landlord of that facility in accordance with the stipulation and
      settlement agreement to be signed simultaneously with this
      agreement.

	7.  	
      SUBSTITUTION
      OF STOCK CERTIFICATES ISSUED BY DLMC.
      The Company agrees to instruct Pacific Stock Transfer Co to exchange
      100,000 DLMC Common Stock certificate previously issued to Mack for a new
      certificate evidencing Mack’s ownership of 100,000 DLMC stock. This stock
      will have endorsed on it that the shares are subject to restriction as are
      applicable by SEC regulations in force at the time of this agreement. This
      should be done within 3 days of signing of this
  document.

Digital
Learning Management Corporation - Non-Stop Education

Page 2 of 
3 

 

	 	 	
      
       

	 	 	 
	 	 	
      
      Digital
      Learning Management Corporation

      19950
      Mariner Avenue.

      Torrance,
      Calif. 90503 (USA)

      Phone:
      (310) 921-3444; Fax: (310) 921-2878

      www.dlmcweb.com

       

       

 

7.
RETURN OF COMPANY OWNED PROGRAMS AND DATA: At the
time of signing this agreement, Mack agrees to return to the Company all
Financial Data, Business and Sales Data, Licensed Programs and any other Company
information in his possession either in hard-copy format or Digital Format
stored on his hard drive, CD on other Company property.

8.
GUARANTY AND UNDERTAKING: By
signing this agreement, DLMC acknowledges that they will Indemnify and hold
harmless Mack Mahmood and Aslam Ali for any Global liabilities which were
incurred after April 30, 2004 and further state that Mack Mahmood and Aslam Ali
will not be required to pay any liabilities of Global which Global might
continue to incur till such a time that Mack Mahmood and Aslam Ali are removed
as officers from the Global corporation. 

9.
STATEMENT
OF INFORMATION: DLMC agrees that it will cause GLOBAL to file with the Secretary
of State a Statement of Information removing Aslam Ali and Mack Mahmood as
officers of GLOBAL. 

10.
It is the
intent of the parties that by consummation of this agreement all disputes
between DLMC/Global and Mack and Ali shall be resolved and the parties agree
that if the terms of this agreement are adhered to neither party will commence
any legal action against the other. All parties further agree to execute any
further documents as may be reasonably required to carry out the purpose and
intent of this agreement. Any such documents if presented by the Company shall
be executed without unreasonable delays.

	Executed on May 2, 2005	 	 
	 	 	 
	Dated: ___
      May 2, 2005	
       BY: 
	/s/
      Mack Mahmood
	 	 	MACK MAHMOOD
		 	 
	 	 	DIGITAL LEARNING MANAGEMENT
    CORPORATION
	 	 	AND GLOBAL COMPUTER SYSTEMS, INC. 
	 	 	 
	 	 	 
	Dated: ___
      May 2, 2005	
       BY:
	/s/
      Aurangzeb Bhatti
	 	 	
      AURANGZEB
      BHATTI, President 

 

Digital
Learning Management Corporation - Non-Stop Education

Page 3 of 
3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}]]